title: The effects of midazolam and dexmedetomidine infusion on peri-operative anxiety in regional anesthesia.
abstract: BACKGROUND
  This study aimed to compare the influences ofmidazolam and dexmedetomidine infusion on anxiety scores in patients undergoing surgery with regional anesthesia.
  
  
  METHODS
  Eighty ASA I or II class patient undergoing elective surgery with regional anesthesia were included in the study. Permanent anxiety scores were determined using the State-Trait Anxiety Inventory (STAI)-1 and 2 one day before the surgery. In Group I patients, dexmedetomidine 0.5 micro g/kg basal infusion for 10 min and 0.5 micro g/kg/h for maintenance was administered. In Group II patients, midazolam infusion at a rate of 0.05 mg/kg for 10 min and 0.05 mg/kg/h for maintenance was administered. The sedation scores were determined every 5 min. The steady state anxiety scores of the patients were determined one day before, 30 min after operation, at the end of the operation, and at 30 min and day 7 postoperatively using STAI-1 score. Side effects were determined and recorded.
  
  
  RESULTS
  Sedation scores were comparable in both of two treatment groups. Anxiety scores were maintained with drug infusions. The incidences of side effects were significantly decreased in midazolam group compared to the dexmedetomidine group.
  
  
  CONCLUSIONS
  Midazolam infusion was found to be more appropriate and efficient than dexmedetomidine during regional anesthesia practice. Dexmedetomidine infusion should be cautiously used in regional anesthetic techniques performing symphathetic blockade.
authors.affiliation: Department of Anesthesiology, Kirikkale University, Faculty of Medicine, Ankara Turkey.
authors.forename: Elif
authors.initials: E
authors.lastname: Senses
authors.forename: Alparslan
authors.initials: A
authors.lastname: Apan
authors.forename: Emine Arzu
authors.initials: EA
authors.lastname: Köse
authors.forename: Gökşen
authors.initials: G
authors.lastname: Oz
authors.forename: Hatice
authors.initials: H
authors.lastname: Rezaki
mesh_terms: D000328:Adult; D000765:Anesthesia, Conduction; D001007:Anxiety / Q000517:prevention & control*; D001794:Blood Pressure / Q000187:drug effects; D020927:Dexmedetomidine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use*; D007262:Infusions, Intravenous; D008297:Male; D008874:Midazolam / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D059035:Perioperative Period
chemical_list: D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine; D008874:Midazolam